Literature DB >> 17214348

Expression of vascular endothelial growth factor in malignant mesothelioma.

Keisuke Aoe1, Akio Hiraki, Takehiro Tanaka, Ken-Ichi Gemba, Koji Taguchi, Tomoyuki Murakami, Naoko Sueoka, Toshiaki Kamei, Hiroshi Ueoka, Kazuro Sugi, Tadashi Yoshino, Takumi Kishimoto.   

Abstract

Malignant mesothelioma is the most common primary pleural neoplasm. Angiogenesis is an important component of a variety of pathological processes, including carcinogenesis and tumor metastases. Vascular endothelial growth factor (VEGF) is the most potent known endothelial, cell specific mitogen. The authors assessed the relation between VEGF expression and clinicopathological variables or overall survival, in malignant mesothelioma. We studied 37 patients with malignant pleural mesothelioma and found that 36 out of 37 (97.3%) malignant mesothelioma samples were stained positively for VEGF. An increased expression of VEGF was observed in the epithelioid type compared with the other histological types of malignant mesothelioma, including the biphasic and sarcomatoid types. No statistically significant association was observed between VEGF expression and gender, age, or clinical stage. Furthermore, the expression of VEGF did not impact on the survival of patients with malignant mesothelioma. Although VEGF expression might be important for tumor development and maintenance, it was not identified as a prognostic factor in malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214348

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).

Authors:  Kaushal Parikh; Sumithra J Mandrekar; Katie Allen-Ziegler; Brandt Esplin; Angelina D Tan; Benjamin Marchello; Alex A Adjei; Julian R Molina
Journal:  Oncologist       Date:  2019-12-24

Review 2.  Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"

Authors:  Vincenzo Di Noia; Emanuele Vita; Miriam Ferrara; Antonia Strippoli; Michele Basso; Giovanni Schinzari; Alessandra Cassano; Emilio Bria; Carlo Barone; Ettore D'Argento
Journal:  Curr Treat Options Oncol       Date:  2019-02-21

3.  Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1).

Authors:  Jedd M Hillegass; Arti Shukla; Maximilian B MacPherson; Jeffrey P Bond; Chad Steele; Brooke T Mossman
Journal:  J Toxicol Environ Health A       Date:  2010

4.  Dysregulation of microRNAs and tRNA-derived ncRNAs in mesothelial and mesothelioma cell lines after asbestiform fiber exposure.

Authors:  Alfredo Pulvirenti; Carla Loreto; Veronica Filetti; Alessandro La Ferlita; Antonio Di Maria; Venera Cardile; Adriana C E Graziano; Venerando Rapisarda; Caterina Ledda
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

5.  Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy.

Authors:  Terence C Chua; Peng Yao; Javed Akther; David L Morris
Journal:  Pathol Oncol Res       Date:  2009-10-01       Impact factor: 3.201

Review 6.  Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.

Authors:  Hui Liu; Licun Wu; Kai Ji; Wei Wang
Journal:  Tumour Biol       Date:  2015-09-11

Review 7.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

Review 8.  A Glimpse in the Future of Malignant Mesothelioma Treatment.

Authors:  Gaetano Pezzicoli; Mimma Rizzo; Martina Perrone; Silvia Minei; Luciano Mutti; Camillo Porta
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

9.  Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Authors:  Marco Tomasetti; Lory Santarelli
Journal:  Cancers (Basel)       Date:  2010-04-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.